Thymulin

• Thymulin (FTS, facteur thymique sérique) is a nonapeptide thymic hormone whose biological activity is strictly ZINC-DEPENDENT — without a bound zinc ion it is inactive. This is its single most defining feature.
• Falling thymulin activity is one of the EARLIEST markers of zinc deficiency, dropping before serum or red-cell zinc do — which is why much of the interest is diagnostic/physiologic rather than as an injectable.
• It supports T-cell differentiation and NK-cell development and, in animal models, sensitizes end-organs to hormone signaling (e.g. ACTH, hCG) — linking the immune system to the endocrine system.
• Evidence is predominantly preclinical. It is NOT FDA-approved, has no established human dose, and has a very short half-life — so the practical research emphasis is on supporting endogenous production via adequate zinc, not injection.

Thymulin is a small thymic hormone first characterized by the French immunologist Jean-François Bach (originally as 'facteur thymique sérique', FTS). It is produced by thymic epithelial cells and is unusual among peptides in that it only works when complexed with zinc — the zinc-bound form ('zinc-thymulin') is the active molecule.

It sits in the same broad 'thymic peptide' conversation as thymosin alpha-1 and thymosin beta-4 / TB-500, but it is a distinct compound with a distinct, zinc-gated mechanism. Everything below is research context, not medical guidance; thymulin is not an approved therapy.

Thymulin is a nonapeptide (nine amino acids) secreted by the thymus. Its defining property is zinc-dependence: the peptide must bind a zinc ion to adopt its active conformation and exert biological effects. The amount of active thymulin in circulation therefore reflects both thymic output and zinc availability.

Because of that coupling, thymulin is studied as much as a readout of zinc and thymic status as it is a candidate intervention.

Active (zinc-bound) thymulin promotes the differentiation and maturation of T-cells and the development of natural-killer (NK) cells, and helps modulate the balance of pro- and anti-inflammatory cytokines. In animal models it has a striking 'end-organ sensitization' effect: paired with a stimulating hormone such as ACTH or hCG, it produces greater target-hormone output than the stimulating hormone alone, creating a feedback link between immune status and reproduction/stress hormones. Preclinical work also reports analgesic and anti-inflammatory effects in the nervous system.

This is the practical heart of thymulin. Active thymulin levels fall when zinc is insufficient — and they fall early, before standard blood-zinc measures change — making thymulin one of the most sensitive functional markers of zinc status. The corollary, emphasized in the research, is that restoring adequate zinc can restore thymulin activity, which is why the field's interest leans toward optimizing zinc rather than administering the peptide itself.

Thymulin's effects are inseparable from zinc status — its activity is gated by zinc, so it cannot be evaluated (or used) in isolation from a person's zinc levels.

There is no FDA-approved or established human dose for thymulin. Its circulating half-life is very short (on the order of minutes), so direct administration is impractical as a standalone protocol, and animal studies use microgram-range parenteral dosing in controlled settings. The recurring practical takeaway from the literature is to support endogenous thymulin by ensuring adequate zinc rather than injecting the peptide.

Human safety data is sparse, and thymulin should be treated as experimental. Reported toxicity in animal models is generally low, but because its activity is strictly zinc-dependent its effects cannot be separated from zinc status. There is no established human safety profile, pharmacokinetics, or long-term data. Not recommended in pregnancy/breastfeeding.

• Foundational work (Bach, Dardenne and colleagues): identified FTS/thymulin and established that zinc is required for its biological activity.
• Zinc-status studies: thymulin activity falls early in zinc deficiency and is restored by zinc repletion — positioning it as a sensitive functional marker of zinc status.
• Immune-endocrine models: thymulin sensitizes end-organs to ACTH/hCG and modulates T-cell/NK-cell development and cytokine balance.
• Neuroinflammation/analgesia: preclinical reports of anti-inflammatory and analgesic effects in the nervous system.

Most thymulin findings are animal/mechanistic. There is no body of large human trials to draw efficacy or dosing conclusions from.

On the Huberman Lab podcast, Dr. Abud Bakri singled thymulin out as the under-recognized thymic hormone — distinct from thymosin alpha-1 and TB-500 — and emphasized the zinc dependence: because falling thymulin is the earliest sign of zinc depletion, his framing was that the goal should be to BOOST endogenous thymulin through adequate zinc rather than to inject it (given its very short half-life).

He raised it as part of a larger argument that the thymus is the field's most underrated target for immune resilience and healthy aging. As with the rest of that discussion, this is expert opinion grounded in mostly preclinical data, not a treatment recommendation.

Expert commentary from a podcast; thymulin is not FDA-approved and the practical emphasis is zinc sufficiency, not peptide injection.

Thymulin is not FDA-approved and is sold (where sold) as a research chemical for laboratory use only, not intended for human consumption. Note: its status on anti-doping lists is not as clearly defined as thymosin beta-4 / TB-500 (which is explicitly WADA-prohibited) — tested athletes should consult the current WADA Prohibited List directly rather than rely on a category inference.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.